Abivax Provides 2026 Corporate Outlook
Globe Newswire (Wed, 7-Jan 4:05 PM ET)
Abivax to be Added to Nasdaq Biotechnology Index
Globe Newswire (Thu, 18-Dec 4:05 PM ET)
Obefazimod Shows Potential Anti-Fibrotic Effect as Abivax Presents Expansive Data at ECCO 2026
Market Chameleon (Thu, 18-Dec 3:46 AM ET)
Globe Newswire (Wed, 17-Dec 4:05 PM ET)
Abivax Presents Third Quarter 2025 Financial Results
Globe Newswire (Mon, 15-Dec 4:07 PM ET)
Abivax's Obefazimod Shows Promising Patient-Reported Outcomes in Ulcerative Colitis Phase 3 Trials
Market Chameleon (Tue, 4-Nov 2:22 AM ET)
Market Chameleon (Mon, 6-Oct 3:08 AM ET)
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Abivax SA - American Depositary Shares trades on the NASDAQ stock market under the symbol ABVX.
As of February 10, 2026, ABVX stock price declined to $119.18 with 535,317 million shares trading.
ABVX has a beta of 2.27, meaning it tends to be more sensitive to market movements. ABVX has a correlation of 0.04 to the broad based SPY ETF.
ABVX has a market cap of $9.42 billion. This is considered a Mid Cap stock.
Last quarter Abivax SA - American Depositary Shares reported $8 million in Revenue and -$1.47 earnings per share. This beat revenue expectation by $6 million and missed earnings estimates by -$.57.
The top ETF exchange traded funds that ABVX belongs to (by Net Assets): IBB, MSSM, FRTY, PINK, ONEQ.
ABVX has outperformed the market in the last year with a return of +1791.7%, while the SPY ETF gained +16.4%. In the last 3 month period, ABVX beat the market returning +13.2%, while SPY returned +3.4%. However, in the most recent 2 weeks ABVX has underperformed the stock market by returning -1.4%, while SPY returned -0.1%.
ABVX support price is $114.69 and resistance is $124.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABVX shares will trade within this expected range on the day.
